Home News

First half 2021 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Wed, 28/07/2021 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI achieves an increase of 52% in operating income and 75% in EBITDA
Laboratorios Farmacéuticos Rovi, SA (BME: ROVI), company Pan-European pharmaceutical company specialized and dedicated to the research...
6 min
28/07/2021
ROVI holds its 2021 General Shareholders Meeting
ROVI holds its 2021 General Shareholders Meeting
Laboratorios Farmaceuticos Rovi, SA has held its today General Ordinary Shareholders Meeting, in which a valuation of the 2020 financial...
6 min
17/06/2021
The President of the Spanish government, Pedro Sánchez, makes an institutional...
During their visit to the facilities, they have been accompanied by the CEO of ROVI, Juan López-Belmonte; the vice president and CFO,...
2 min
14/05/2021